Takeda Pharmaceutical Company Limited | TalkMarkets

Latest Posts

About This Stock More About This Stock

More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024

Article By: Tyler Durden

Thursday, January 4, 2024 1:10 AM EDT

More than 140 brands of drugs are going to see their prices hiked heading into the new year

In this article: GSK, PFE, SNY, TAK

Read

Week In Review: China's Biopharmas Announce $2.5 Billion In Deals

Article By: ChinaBio® Today

Saturday, October 21, 2023 1:39 PM EDT

KBP Biosciences sold global rights for its hypertension candidate to Novo Nordisk in an agreement worth up to $1.3 billion. Also, EpimAb Bio sold the rights to use its Fabs-In-Tandem Immunoglobulin platform to Almirall in a $210 million agreement.

In this article: SRXXF, BGNE, WXXWY, ASPHF, NVO, LBTSF, TAK

Read

Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration

Article By: ChinaBio® Today

Saturday, July 8, 2023 2:18 PM EDT

F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic therapy developed by VBI Vaccines for $15 million.

In this article: TAK, BRIBF Also: MRNA, ARGX, VBIV, ZLAB, IVBXF

Read

Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug

Article By: ChinaBio® Today

Saturday, January 28, 2023 3:00 PM EDT

Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion, HutchMed will also pay royalties on net sales.

In this article: HCM, TAK Also: SMMT, LEGN, SBHMY, SHJBF, ASCLF

Read